Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 1544 • ACR Convergence 2023
Increased Risk of Severe Infection in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: A Population-based Trend Analysis
Kai Zhao¹, J. Antonio Avina-Zubieta², Hui Xie³, Natasha Dehghan⁴ and John Esdaile², ¹Arthritis Research Canada, Coquitlam, BC, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Simon Fraser University, Richmond, BC, Canada, ⁴University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of multisystem inflammatory diseases. One of the most serious and common side-effects of GC and…
Abstract Number: 2380 • ACR Convergence 2023
Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data
Chan-Bum Choi¹, Jung-Min Shin², Nayeon Choi³ and Soorack Ryu³, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea, ³Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, South Korea
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare systemic autoimmune disease with varying reports of incidence rates and clinical manifestations. Renal involvement is one of the…
Abstract Number: 0674 • ACR Convergence 2023
Efficacy and Safety of Mepolizumab During Maintenance Therapy in Patients with Eosinophilic Granulomatosis with Polyangiitis
Daiki Sakai¹, Kaichi Kaneko¹, Karin Furukawa², Mai Kawazoe², Yasuo Matsuzawa³ and Toshihiro Nanki², ¹Division of Rheumatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, ³Division of Respiratory Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, hyper-eosinophilia, and progressive multiorgan organ involvement. Mepolizumab (MPZ) is a humanized monoclonal…
Abstract Number: 0725 • ACR Convergence 2023
Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Sophie Nagle¹, Yann Nguyen², Xavier Puéchal³, Dimitri Titeca-Beauport⁴, Thomas Crépin⁵, Rafik Mesbah⁶, Idris Boudhabhay⁷, Gregory Pugnet⁸, Juliette Woessner⁹, Roderau Outh¹⁰, Céline Lebas¹¹, Antoine Néel¹², alexandre Karras¹³, Eric Hachulla¹¹, Benjamin Subran¹⁴, Philippe Kerschen¹⁵, Mathieu Gerfaud-Valentin¹⁶, Stéphane Vinzio¹⁷, Tiphaine Goulenok¹⁸, Raphael Borie¹⁹, Sébastien Humbert²⁰, Yurdagul Uzunhan²¹, Sarah Melboucy-Belkhir²², Jean-Baptiste Gouin²³, Mary-Jane Guerry²⁴ and Benjamin Terrier²⁵, ¹AP-HP Cochin Hospital, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁴CHU Amiens, Amiens, France, ⁵Amiens University Hospital, Amiens, France, ⁶Boulogne Hospital (CH), Boulogne, France, ⁷Necker University Hospital, Paris, France, ⁸CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ⁹Avignon Hospital (CH), Avignon, France, ¹⁰Perpignan Hospital (CH), Perpignan, France, ¹¹Lille University Hospital, Lille, France, ¹²CHU Nantes, Nantes, France, ¹³HEGP - APHP, Paris, France, ¹⁴Croix Saint Simon Hospital, Paris, France, ¹⁵Department of Neurology, Luxembourg Hospital Center, Luxembourg City, Luxembourg, ¹⁶Lyon University Hospital, Lyon, France, ¹⁷Grenoble Hospital (CH), Grenoble, France, ¹⁸Assistance Publique Hopitaux de Paris, Paris, France, ¹⁹Bichat-Claude Bernard, Universite de Paris, Paris, France, ²⁰Besançon University Hospital, Besançon, France, ²¹AP-HP, Bobigny, France, ²²Saint Quentin Hospital, Saint-Quentin, France, ²³Vannes Hospital (CH Bretagne Atlantique), Vannes, France, ²⁴Valenciennes Hospital (CH), Valenciennes, France, ²⁵Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: Glucocorticoids (GCs) in combination with rituximab (RTX) or cyclophosphamide are the cornerstone of treatment for patients with severe granulomatosis with polyangiitis (GPA) and microscopic…
Abstract Number: 1545 • ACR Convergence 2023
Validation of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA-associated Vasculitis
Liubov Petelytska, Vladyslav Kravchenko and Oleg Iaremenko, Bogomolets National Medical University, Kyiv, Ukraine
Background/Purpose: The early diagnosis of ANCA-associated vasculitis (AAV) and treatment initiation may prevent progression to end organ damage, particularly renal disease. Based on the Vasculitis…
Abstract Number: 2381 • ACR Convergence 2023
ANCA-associated Vasculitis and Renal Disease in a Multidisciplinary Outpatient Clinic in Northern Spain
Salma Al Fazazi¹, Fabricio Benavides², Vanesa Calvo Río³, maria rodriguez Vidriales², clara escagedo Cagigas², monica renuncio garcia², luis martin penagos⁴ and Ricardo Blanco⁵, ¹Hospital Universitario Puerta Del Mar, Cádiz, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴Division of Nephrology, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-DIVAL, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The severity of clinical features and outcomes in previous series of patients reported with renal disease related to ANCA-associated vasculitis (AAV) vary greatly, probably…
Abstract Number: 0675 • ACR Convergence 2023
Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond
allyson egan¹, Pasupathy Sivasothy² and David Jayne³, ¹Trinity Health Kidney Centre, Tallaght University Hospital, Ireland, Dublin, Ireland, ²Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ³University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…
Abstract Number: 0854 • ACR Convergence 2023
Long-term Efficacy of Remission-induction Regimens for Eosinophilic Granulomatosis with Polyangiitis
Martin Dutertre¹, Gregory Pugnet², Claire De Moreuil³, Bernard Bonnotte⁴, YGAL BENHAMOU⁵, Dominique Chauveau⁶, Elisabeth Diot⁷, Pierre Duffau⁸, Nicolas Limal⁹, Antoine Néel¹⁰, GEOFFREY URBANSKI¹¹, Noémie Jourde-Chiche¹², Nicolas MARTIN SILVA¹³, Francois Maurier¹⁴, Arsène Mekinian¹⁵, Nicolas Schleinitz¹⁶, Felix ackermann¹⁷, Anne-Laure Fauchais¹⁸, Antoine Froissart¹⁹, Thomas Le Gallou²⁰, Yurdagul Uzunhan²¹, Jean-Francois Viallard²², Alice Berezne²³, laurent chiche²⁴, Bruno Crestani²⁵, Guillaume Direz²⁶, Cecile-Audrey DUREL²⁷, Pascal Godmer²⁸, Jean-Emmanuel Kahn²⁹, Marc Lambert³⁰, Mathilde de Menthon¹, Thomas Quemeneur³¹, Jacques Cadranel¹, Pierre Charles³², Antoine Dossier¹, Loic Guillevin³³, Xavier Puéchal³⁴ and Benjamin Terrier³⁵, ¹AP-HP, Paris, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³CHU de Brest, Brest, France, ⁴Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ⁵rouen university hospital, Rouen, France, ⁶Hôpital Le Tripode, Bordeaux, France, ⁷Service de médecine interne et immunologie clinique, CHU Tours, Tours, France, ⁸CHU Bordeaux, Bordeaux, France, ⁹AP-HP, Créteil, France, ¹⁰CHU de Nantes, Nantes, France, ¹¹CHU Angers, Angers, France, ¹²AP-HM, Marseille, France, ¹³CHU Caen, Caen, France, ¹⁴Hôpitaux privés de Metz, Vaux / Frankreich, France, ¹⁵Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ¹⁶Aix Marseille university, AP-HM, Marseille, France, ¹⁷Hôpital Foch, Suresnes, France, ¹⁸Dupuytren Hospital, Limoges, France, ¹⁹CHI Créteil, Créteil, France, ²⁰CHU Rennes, Rennes, France, ²¹AP-HP, Bobigny, France, ²²CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France, ²³CH Annecy, Annecy, France, ²⁴Hopital Europeen, Marseille, France, ²⁵Hopital Bichat, Paris University, Paris, France, ²⁶CH Le Mans, Le Mans, France, ²⁷Hospices Civils de Lyon, Lyon, France, ²⁸CH Bretagne Atlantique, Vannes, France, ²⁹AP-HP, Suresnes Cedex, France, ³⁰CHRU Lille, Lille, France, ³¹CH Valenciennes, Valenciennes, France, ³²Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, ³³University Paris Descartes, Paris, France, ³⁴National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ³⁵Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The Rituximab in Eosinophilic Granulomatosis With Polyangiitis (REOVAS) trial compared rituximab (RTX) infusions to conventional strategy for remission-induction in eosinophilic granulomatosis with polyangiitis (EGPA).…
Abstract Number: 1550 • ACR Convergence 2023
Importance of Shared Decision-Making for Patients with ANCA-Associated Vasculitis
Jo Robson¹, Montserrat Díaz Encarnación², Peter Verhoeven³, Raquel Olivenza⁴, Monica Balcells⁴, Sara Monti⁵ and Andreas Kronbichler⁶, ¹University of the West of England, Bristol, United Kingdom, ²Autonoma de Barcelona University, Barcelona, Spain, ³Vasculitis Stichting, Silvolde, Netherlands, ⁴CSL Vifor, Glattbrugg, Switzerland, ⁵Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁶Department of Internal Medicine IV (Nephrology and Hypertension), Innsbruck, Austria
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare autoimmune disease associated with significant morbidity. It can present at any age and treatment needs change over time.…
Abstract Number: 2382 • ACR Convergence 2023
Relapse of Patients with ANCA-associated Vasculitis Who Are on Dialysis
Yeo-Jin Lee¹, Hansun Song², Wook Jang Seo³, Jinseok Kim⁴, Soo-Min Ahn¹, Ji-Seon Oh⁵, Yong-Gil Kim², Chang-Keun Lee¹, Bin Yoo¹ and Seokchan Hong¹, ¹Asan Medical Center, Seoul, South Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ³Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea, ⁴Department of Rheumatology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju-si, Jeju-do, South Korea, La Jolla, CA, South Korea, ⁵Department of Information Medicine, Big Data Research Center, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, South Korea
Background/Purpose: It is known that disease activity of ANCA-associated vasculitis (AAV) is decreased after dialysis. However, most studies have been conducted on Caucasians, and factors…
Abstract Number: 0677 • ACR Convergence 2023
Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan
SOKO KAWASHIMA¹, Yoshinori Komagata¹, Mitsumasa Kishimoto² and Shinya Kaname¹, ¹Kyorin University School of Medicine, Tokyo, Japan, ²Kyorin University School of Medicine, Yokohoma, Japan
Background/Purpose: Contrary to Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan or Asian countries. It is possible that therapeutic responses to EGPA with mepolizumab…
Abstract Number: 0855 • ACR Convergence 2023
Real-world Experience with Avacopan in ANCA Vasculitis: A Multi-center Retrospective Cohort Analysis
Sebastian Sattui¹, Colin Diffie², Aisha Shaikh³, Julia Ford⁴, David Bulbin⁵, Ora Gewurz-Singer⁶, Faten Aqeel⁷, Reza Zonozi⁸, Abdallah Sassine Geara⁹, Dustin Le⁷, Gabriel Sauvage⁸, Madeline Chung¹⁰, Isabelle Ayoub¹⁰, Frank Cortazar¹¹, Andrew Bomback¹², Karina Guaman¹², Jason George¹³, John Niles⁸ and Duvuru Geetha⁷, ¹University of Pittsburgh, Pittsburgh, PA, ²Washington University, St. Louis, MO, ³Washington University in St. Louis, St. Louis, MO, ⁴University of Michigan, Ann Arbor, MI, ⁵Geisinger Health System, Danville, PA, ⁶University of Michigan, Huntington Woods, MI, ⁷Johns Hopkins University, Baltimore, MD, ⁸Massachusetts General Hospital, Boston, MA, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Ohio State University, Columbus, OH, ¹¹New York Nephrology, Watervliet, NY, ¹²Columbia University, New York, NY, ¹³Geisenger Health, Danville, PA
Background/Purpose: Avacopan (AVP) is a recently approved adjunct therapy for remission induction of ANCA-associated vasculitis (AAV). Data on real-world use of AVP in AAV are…
Abstract Number: 1551 • ACR Convergence 2023
Measurement of Sinonasal Disease Activity in Granulomatosis with Polyangiitis
Roger Yang¹, Ellen Romich², Shubhasree Banerjee³, Naomi Amudala³, Peter Merkel³, Joshua Baker³ and Rennie Rhee³, ¹University of Pennsylvania, Montréal, QC, Canada, ²Hospital of the University of Pennsylvania, Media, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: In granulomatosis with polyangiitis (GPA), sinonasal inflammation can be severe and significantly impact quality of life. Little is known about the most effective local…
Abstract Number: 2383 • ACR Convergence 2023
Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Dual Positive Anti-Neutrophil Cytoplasmic Antibody and Anti-Glomerular Basement Membrane Antibody: A Single Center Experience
Zaina Shahid, Michael Lucke and Swati Arora, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Knowledge of disease characteristics and long-term outcomes of dual-positive patients (DPP) exhibiting anti-neutrophil cytoplasmic antibodies (ANCA) and anti-glomerular basement membrane (GBM) antibodies is limited…
Abstract Number: 0679 • ACR Convergence 2023
Long-term Safety of Rituximab (Mabthera) in Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA): Rituximab Surveillance Study in VASculitis (RIVAS)
Lisa Uchida¹, Dr Rachel Jones², Rona Smith¹, Claudia Loechel³, Maria King³, Marianna Nodale⁴, Simon Bond⁴, Raashid Luqmani⁵, David Gray⁵, Joe Barrett⁵ and David Jayne⁶, ¹Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Vasculitis and Lupus Clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, ⁴Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, ⁵Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Rituximab is a first-line treatment for remission induction and the prevention of relapse in ANCA-associated vasculitis (AAV). There is a paucity of real-world data…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].